Esperion Therapeutics, Inc. (NASDAQ:ESPR) is set to announce third quarter earning results on Monday 2nd November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ESPR to report 3Q20 loss of $ 3.44 per share.
For the full year, analysts anticipate top line of $ 259.34 million, while looking forward to loss of $ 4.43 per share bottom line.
Previous Quarter Performance
Esperion Therapeutics, Inc. posted income for the second quarter of $ 4.32 per share, from the revenue of $ 212.24 million. Wall street analysts are predicting, ESPR to report 2Q20 income of $ 1.71 per share from revenue of $ 147.97 million. The bottom line results beat street analysts by $ 2.61 or 152.63 percent, at the same time, top line results outshined analysts by $ 64.27 million or 43.43 percent.
Stock Performance
On Friday, shares of Esperion Therapeutics, Inc. has traded high as $ 31.54 and has cracked $ 29.66 on the downward trend, reaching $ 29.97 with volume of 712.30 thousand shares.
According to the previous trading day, closing price of $ 29.97, representing a 26.35 % increase from the 52 week low of $ 24.82 and a 59.26 % decrease over the 52 week high of $ 76.98.
The company has a market capital of $ 853.12 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th October 2020, maintained by Bank of America at Buy rating, with $ 52.00 target price.
Conference Call
Esperion Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.esperion.com
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH.
